Eng King Tan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2360219/publications.pdf

Version: 2024-02-01

		57758	69250
271	8,687	44	77
papers	citations	h-index	g-index

284	284	284	11686
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVID-19 vaccination and cultural tightness. Psychological Medicine, 2023, 53, 1124-1125.	4.5	10
2	Unravelling Pathophysiology of Neurological and Psychiatric Complications of COVID-19 Using Brain Organoids. Neuroscientist, 2023, 29, 30-40.	3.5	24
3	Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination. QJM - Monthly Journal of the Association of Physicians, 2022, 114, 807-809.	0.5	17
4	Increased expression of pathological markers in Parkinsonâ€™s disease dementia post-mortem brains compared to dementia with Lewy bodies. BMC Neuroscience, 2022, 23, 3.	1.9	7
5	Longitudinal Study of SNCA Rep1 Polymorphism on Executive Function inÂEarly Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, , 1-6.	2.8	0
6	COVID-19 vaccination precipitatingde novoANCA-associated vasculitis: clinical implications. CKJ: Clinical Kidney Journal, 2022, 15, 1010-1011.	2.9	4
7	Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions. Nature Reviews Neurology, 2022, 18, 145-157.	10.1	17
8	Stroke-related restless legs syndrome: epidemiology, clinical characteristics and pathophysiology. Sleep Medicine, 2022, 90, 238-248.	1.6	5
9	Survival outcome of haemodialysis and peritoneal dialysis. Annals of the Academy of Medicine, Singapore, 2022, 51, 132-133.	0.4	1
10	Parkinsonâ€™s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender. Aging, 2022, 14, 2148-2173.	3.1	14
11	Editorial: The Role of Neurovascular Unit in Neurodegeneration. Frontiers in Cellular Neuroscience, 2022, 16, 870631.	3.7	1
12	Parkinsonâ€™s Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1. Cells, 2022, 11, 1649.	4.1	4
13	Prognosis of Guillainâ€“BarrÃ© Syndrome Linked to COVID-19 Vaccination. Brain Sciences, 2022, 12, 711.	2.3	3
14	Blood Lipid Biomarkers in Early Parkinsonâ€™s Disease and Parkinsonâ€™s Disease with Mild Cognitive Impairment. Journal of Parkinson's Disease, 2022, 12, 1937-1943.	2.8	6
15	Association Between Parkinsonâ€™s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1737-1748.	2.8	9
16	Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway. Human Molecular Genetics, 2022, 31, 3886-3896.	2.9	1
17	Upregulated Blood miR-150-5p in Alzheimerâ€™s Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-Î², and Cerebral Atrophy. Journal of Alzheimer's Disease, 2022, 88, 1567-1584.	2.6	2
18	Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinsonâ€™s disease. Briefings in Bioinformatics, 2021, 22, .	6.5	20

#	Article	IF	Citations
19	Association analysis of PSAP variants in Parkinsonâ€™s disease patients. Brain, 2021, 144, e9-e9.	7.6	6
20	Subjective cognitive Complaints in early Parkinson's disease patients with normal cognition are associated with affective symptoms. Parkinsonism and Related Disorders, 2021, 82, 24-28.	2.2	21
21	Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19. Lancet Neurology, The, 2021, 20, 10-12.	10.2	3
22	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. Parkinsonism and Related Disorders, 2021, 82, 146-149.	2.2	7
23	Symbiotic bacteria attenuate Drosophila oviposition repellence to alkaline through acidification. Insect Science, 2021, 28, 403-414.	3.0	7
24	Remote Prescription During Pandemic: Challenges and Solutions. Archives of Medical Research, 2021, 52, 450-452.	3.3	6
25	â€œHot cross bunâ€•is a potential imaging marker for the severity of cerebellar ataxia in MSA-C. Npj Parkinson's Disease, 2021, 7, 15.	5.3	20
26	High Diagnostic Utility Incorporating a Targeted Neurodegeneration Gene Panel With MRI Brain Diagnostic Algorithms in Patients With Young-Onset Cognitive Impairment With Leukodystrophy. Frontiers in Neurology, 2021, 12, 631407.	2.4	3
27	Association study of MCCC1/LAMP3 and DGKQ variants with Parkinsonâ€™s disease in patients of Malay ancestry. Neurological Sciences, 2021, 42, 4203-4207.	1.9	5
28	Two heterozygous progranulin mutations in progressive supranuclear palsy. Brain, 2021, 144, e27-e27.	7.6	9
29	The role of gut dysbiosis in Parkinsonâ€™s disease: mechanistic insights and therapeutic options. Brain, 2021, 144, 2571-2593.	7.6	119
30	Aggregation-induced emission (AIE) nanoparticles labeled human embryonic stem cells (hESCs)-derived neurons for transplantation. Biomaterials, 2021, 271, 120747.	11.4	16
31	Gut microbiome modulates Drosophila aggression through octopamine signaling. Nature Communications, 2021, 12, 2698.	12.8	64
32	Transâ€Ethnic Fineâ€Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease. Movement Disorders, 2021, 36, 1805-1814.	3.9	14
33	The splenial angle: a novel radiological index for idiopathic normal pressure hydrocephalus. European Radiology, 2021, 31, 9086-9097.	4.5	6
34	Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP. Neurobiology of Disease, 2021, 153, 105313.	4.4	8
35	Questions on NOTCH2NLC Repeat Expansions in Parkinson Diseaseâ€”Reply. JAMA Neurology, 2021, 78, 763.	9.0	0
36	Case-control study of hypertension and Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 63.	5.3	8

#	Article	IF	Citations
37	Tryptophan-metabolizing gut microbes regulate adult neurogenesis via the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	75
38	Seasonal haze: Knowledge gaps and risk perception behaviours. Annals of the Academy of Medicine, Singapore, 2021, 50, 512-513.	0.4	0
39	Functional Neurological Disorders and <scp>COVIDâ€19</scp> Vaccination. Annals of Neurology, 2021, 90, 328-328.	5.3	6
40	Clinical correlates of white matter lesions in Parkinson's disease using automated multi-modal segmentation measures. Journal of the Neurological Sciences, 2021, 427, 117518.	0.6	6
41	Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort. Movement Disorders, 2021, 36, 2936.	3.9	3
42	Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks. JAMA Internal Medicine, 2021, 181, 1420.	5.1	1
43	Genetic Studies of Parkinson's and Alzheimer's Disease in Latinos/Hispanics: New Insights and Challenges. Annals of Neurology, 2021, 90, 350-352.	5.3	0
44	Lewy Bodyâ€“like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and Î±â€Synuclein Mutations. Annals of Neurology, 2021, 90, 490-505.	5.3	43
45	Utility of quantitative susceptibility mapping and diffusion kurtosis imaging in the diagnosis of early Parkinsonâ€™s disease. NeuroImage: Clinical, 2021, 32, 102831.	2.7	9
46	Stability of MDS-UPDRS Motor Subtypes Over Three Years in Early Parkinson's Disease. Frontiers in Neurology, 2021, 12, 704906.	2.4	4
47	Neurovascular compression in hemifacial spasm. Brain, 2021, , .	7.6	2
48	Fist-Edge-Palm (FEP) test has a high sensitivity in differentiating dementia from normal cognition in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 118060.	0.6	0
49	Applying Artificial Intelligence to Multiâ€Omic Data: New Functional Variants in Parkinson's Disease. Movement Disorders, 2021, 36, 347-347.	3.9	5
50	Essential tremor. Nature Reviews Disease Primers, 2021, 7, 83.	30.5	56
51	Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinsonâ€™s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Frontiers in Immunology, 2021, 12, 794770.	4.8	44
52	ITPKB and ZNF184 are associated with Parkinson's disease risk in East Asians. Neurobiology of Aging, 2020, 86, 201.e15-201.e17.	3.1	4
53	Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications. Neuroscientist, 2020, 26, 170-184.	3.5	12
54	Differentiating Parkinson's disease motor subtypes using automated volumeâ€based morphometry incorporating white matter and deep gray nuclear lesion load. Journal of Magnetic Resonance Imaging, 2020, 51, 748-756.	3.4	20

#	Article	IF	Citations
55	Whole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese. Neurobiology of Aging, 2020, 90, 150.e5-150.e11.	3.1	29
56	Essential tremor-plus: a controversial new concept. Lancet Neurology, The, 2020, 19, 266-270.	10.2	82
57	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. Journal of the Neurological Sciences, 2020, 418, 117105.	0.6	3
58	Messaging Fatigue and Desensitisation to Information During Pandemic. Archives of Medical Research, 2020, 51, 716-717.	3.3	40
59	Olfactory dysfunction and COVID-19. Lancet Psychiatry,the, 2020, 7, 663.	7.4	7
60	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	3.9	57
61	Safeguarding Non-COVID-19 Research: Looking Up from Ground Zero. Archives of Medical Research, 2020, 51, 731-732.	3.3	7
62	Chest CT in asymptomatic COVID-19: benefits and concerns. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1570-1571.	2.0	1
63	Altered striatal dopamine levels in Parkinsonâ€™s disease VPS35 D620N mutant transgenic aged mice. Molecular Brain, 2020, 13, 164.	2.6	10
64	Complete Genome Sequence of Serratia marcescens FY, Isolated from Drosophila melanogaster. Microbiology Resource Announcements, 2020, 9, .	0.6	1
65	Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinsonâ€™s disease. Stem Cell Research and Therapy, 2020, 11, 347.	5.5	8
66	Gutâ€“Brain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 849.	2.4	13
67	Association of NOTCH2NLC Repeat Expansions With Parkinson Disease. JAMA Neurology, 2020, 77, 1559.	9.0	66
68	Various Diseases and Clinical Heterogeneity Are Associated With â€œHot Cross Bunâ€• Frontiers in Aging Neuroscience, 2020, 12, 592212.	3.4	21
69	Association between plasma neurofilament light chain levels and cognition in early Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e040206.	0.8	2
70	New Insights into Immune-Mediated Mechanisms in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9302.	4.1	16
71	Appropriateness of MRI brain orders: Application of American and British guidelines. Journal of the Neurological Sciences, 2020, 414, 116874.	0.6	2
72	Mental health of scientists in the time of COVID-19. Brain, Behavior, and Immunity, 2020, 88, 956.	4.1	14

#	Article	IF	Citations
73	Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinsonâ€™s disease. Ageing Research Reviews, 2020, 62, 101107.	10.9	40
74	<scp>NOTCH2NLC GGC</scp> Repeat Expansions Are Associated with Sporadic Essential Tremor: Variable Disease Expressivity on Longâ€Term Followâ€up. Annals of Neurology, 2020, 88, 614-618.	5.3	36
75	The role of IgA in COVID-19. Brain, Behavior, and Immunity, 2020, 87, 182-183.	4.1	92
76	Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 33.	10.8	43
77	Patient-Centric Care for Parkinson's Disease: From Hospital to the Community. Frontiers in Neurology, 2020, 11, 502.	2.4	9
78	Capsaicin Functions as Drosophila Ovipositional Repellent and Causes Intestinal Dysplasia. Scientific Reports, 2020, 10, 9963.	3.3	24
79	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. Parkinsonism and Related Disorders, 2020, 72, 82-87.	2.2	25
80	Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study. Movement Disorders, 2020, 35, 1765-1773.	3.9	21
81	Parkinsonâ€™s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 795-808.	1.9	459
82	Evidence of Added Value of Chest CT in Coronavirus Disease (COVID-19) Pneumonia With Initial Negative RT-PCR Results. American Journal of Roentgenology, 2020, 215, W41-W41.	2.2	2
83	Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population. Journal of Clinical Neuroscience, 2020, 72, 63-67.	1.5	2
84	Parkinson disease and the immune system â€” associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	10.1	254
85	Mild Parkinsonian Signs in a Community Ambulant Population. Journal of Parkinson's Disease, 2020, 10, 1231-1237.	2.8	9
86	Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans. JAMA Neurology, 2020, 77, 746.	9.0	170
87	Historical Perspective: Models of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 2464.	4.1	174
88	Physical Activity Improves Anxiety and Apathy in Early Parkinson's Disease: A Longitudinal Follow-Up Study. Frontiers in Neurology, 2020, 11, 625897.	2.4	6
89	Parkinsonâ€™s disease following COVID-19: causal link or chance occurrence?. Journal of Translational Medicine, 2020, 18, 493.	4.4	9
90	Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinsonâ€™s disease. Aging, 2020, 12, 1488-1495.	3.1	15

#	Article	IF	Citations
91	Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinsonâ€™s disease patients with type 2 diabetes mellitus. Aging, 2020, 12, 15682-15704.	3.1	29
92	SNCA Rep1 microsatellite length influences non-motor symptoms in early Parkinson’s disease. Aging, 2020, 12, 20880-20887.	3.1	2
93	Multiple System Atrophy (MSA) and smoking: a meta-analysis and mechanistic insights. Aging, 2020, 12, 21959-21970.	3.1	3
94	Automated analysis of gait and modified timed up and go using the Microsoft Kinect in people with Parkinsonâ€™s disease: associations with physical outcome measures. Medical and Biological Engineering and Computing, 2019, 57, 369-377.	2.8	24
95	The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinsonâ€™s Disease (PD). Cells, 2019, 8, 911.	4.1	69
96	Fully automated leg tracking of Drosophila neurodegeneration models reveals distinct conserved movement signatures. PLoS Biology, 2019, 17, e3000346.	5.6	16
97	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. Cell, 2019, 179, 736-749.e15.	28.9	126
98	LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A caseâ€“control association study for Parkinson's disease. Molecular Genetics & Genomic Medicine, 2019, 7, e604.	1.2	11
99	Current Opinions and Consensus for Studying Tremor in Animal Models. Cerebellum, 2019, 18, 1036-1063.	2.5	27
100	The Characteristics of Patients Associated With High Caregiver Burden in Parkinson's Disease in Singapore. Frontiers in Neurology, 2019, 10, 561.	2.4	15
101	SNCA Rep1 promoter variability influences cognition in Parkinson's disease. Movement Disorders, 2019, 34, 1232-1236.	3.9	13
102	The impact of levodopa therapy-induced complications on quality of life in Parkinsonâ€™s disease patients in Singapore. Scientific Reports, 2019, 9, 9248.	3.3	10
103	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
104	Paroxysmal Movement Disorders: Recent Advances. Current Neurology and Neuroscience Reports, 2019, 19, 48.	4.2	8
105	In utero infection of Zika virus leads to abnormal central nervous system development in mice. Scientific Reports, 2019, 9, 7298.	3.3	20
106	MDS evidenceâ€based review of treatments for essential tremor. Movement Disorders, 2019, 34, 950-958.	3.9	108
107	Parkinsonâ€™s disease GWAS-linked Park16 carriers show greater motor progression. Journal of Medical Genetics, 2019, 56, 765-768.	3.2	6
108	Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinsonâ€™s disease. Translational Neurodegeneration, 2019, 8, 6.	8.0	21

#	Article	IF	Citations
109	Paroxysmal movement disorders: Recent advances and proposal of a classification system. Parkinsonism and Related Disorders, 2019, 59, 131-139.	2.2	13
110	20â€...Clinical characteristics of pathological confirmed early onset dementia with lewy bodies. , 2019, , .		0
111	Role of MicroRNAs in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 5649.	4.1	134
112	Increased Activation of Default Mode Network in Early Parkinsonâ€™s With Excessive Daytime Sleepiness. Frontiers in Neuroscience, 2019, 13, 1334.	2.8	5
113	Potassium channel dysfunction in human neuronal models of Angelman syndrome. Science, 2019, 366, 1486-1492.	12.6	118
114	Amyloid-Î² and Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 2605-2619.	3.6	79
115	PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. Human Molecular Genetics, 2019, 28, 1100-1116.	2.9	48
116	Evaluation of novel Parkinson's disease candidate genes in the Chinese population. Neurobiology of Aging, 2019, 74, 235.e1-235.e4.	3.1	7
117	Four-Year Longitudinal Study of Motor and Non-motor Symptoms in LRRK2-Related Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1379.	2.4	4
118	Positive predictive value of different methods for identifying Parkinson's disease cases in an epidemiological study. Parkinsonism and Related Disorders, 2018, 54, 119-120.	2.2	2
119	Differential White Matter Regional Alterations in Motor Subtypes of Early Drug-Naive Parkinsonâ€™s Disease Patients. Neurorehabilitation and Neural Repair, 2018, 32, 129-141.	2.9	41
120	Case-control analysis of LRRK2 protective variants in Essential Tremor. Scientific Reports, 2018, 8, 5346.	3.3	5
121	Case-control analysis of leucine-rich repeat kinase 2 protective variants in Alzheimer's disease. Neurobiology of Aging, 2018, 64, 157.e7-157.e9.	3.1	3
122	Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease. JAMA Neurology, 2018, 75, 127.	9.0	11
123	Towards better cellular replacement therapies in Parkinson disease. Journal of Neuroscience Research, 2018, 96, 219-221.	2.9	1
124	Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinsonâ€™s disease (PD). Mutation Research - Reviews in Mutation Research, 2018, 778, 72-78.	5.5	30
125	G2019S LRRK2 Increases Stress Susceptibility Through Inhibition of DAF-16 Nuclear Translocation in a 14-3-3 Associated-Manner in Caenorhabditis elegans. Frontiers in Neuroscience, 2018, 12, 782.	2.8	7
126	Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment. Movement Disorders, 2018, 33, 1970-1971.	3.9	17

#	Article	IF	Citations
127	Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study. Parkinsonism and Related Disorders, 2018, 55, 50-54.	2.2	48
128	Identifying genes in Parkinson disease: state of the art. Medical Journal of Australia, 2018, 208, 381-382.	1.7	0
129	Modelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1944-1958.	2.7	18
130	Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement. Neurobiology of Aging, 2018, 68, 160.e15-160.e19.	3.1	14
131	Analysis of GWAS-linked variants in multiple system atrophy. Neurobiology of Aging, 2018, 67, 201.e1-201.e4.	3.1	16
132	DTI Profiles for Rapid Description of Cohorts at the Clinical-Research Interface. Frontiers in Medicine, 2018, 5, 357.	2.6	12
133	Genome-wide association study of Parkinsonâ€™s disease in East Asians. Human Molecular Genetics, 2017, 26, ddw379.	2.9	94
134	Reprogramming of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a R1628P variant in the LRRK2 gene. Stem Cell Research, 2017, 18, 45-47.	0.7	7
135	Development of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient carrying the N551K variant in LRRK2 gene. Stem Cell Research, 2017, 18, 51-53.	0.7	10
136	Derivation of human induced pluripotent stem cell (iPSC) line with LRRK2 gene R1398H variant in Parkinson's disease. Stem Cell Research, 2017, 18, 48-50.	0.7	6
137	Generation of a human induced pluripotent stem cell (iPSC) line carrying the Parkinsonâ€™s disease linked LRRK2 variant S1647T. Stem Cell Research, 2017, 18, 54-56.	0.7	10
138	Risk factors for respiratory failure of motor neuron disease in a multiracial Asian population. Journal of Clinical Neuroscience, 2017, 39, 137-141.	1.5	2
139	Varied pathological and therapeutic response effects associated withCHCHD2mutant and risk variants. Human Mutation, 2017, 38, 978-987.	2.5	21
140	p62-Mediated mitochondrial clustering attenuates apoptosis induced by mitochondrial depolarization. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1308-1317.	4.1	15
141	Targeting LRRK2 in Parkinsonâ€™s disease: an update on recent developments. Expert Opinion on Therapeutic Targets, 2017, 21, 601-610.	3.4	39
142	GWAS-linked PPARGC1A variant in Asian patients with essential tremor. Brain, 2017, 140, e24-e24.	7.6	18
143	Linking statins and lipids in Parkinson's disease. Movement Disorders, 2017, 32, 807-809.	3.9	4
144	Structural connectome alterations in prodromal and de novo Parkinson's disease patients. Parkinsonism and Related Disorders, 2017, 45, 21-27.	2.2	31

#	Article	IF	Citations
145	Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 12559.	3.3	18
146	LRRK2 interacts with ATM and regulates Mdm2â€“p53 cell proliferation axis in response to genotoxic stress. Human Molecular Genetics, 2017, 26, 4494-4505.	2.9	19
147	Genes and Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 111-127.	2.0	11
148	Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinsonâ€™s disease. Science Signaling, 2017, 10, .	3.6	41
149	Mild cognitive impairment in Parkinsonâ€™s disease: a distinct clinical entity?. Translational Neurodegeneration, 2017, 6, 24.	8.0	24
150	B vitamins and cognition in subjects with small vessel disease: A Substudy of VITATOPS, a randomized, placebo-controlled trial. Journal of the Neurological Sciences, 2017, 379, 124-126.	0.6	11
151	Screening for TMEM230 mutations in young-onset Parkinson's disease. Neurobiology of Aging, 2017, 58, 239.e9-239.e10.	3.1	8
152	Characteristics of Chinese-English bilingual dyslexia in right occipito-temporal lesion. Journal of Clinical Neuroscience, 2017, 45, 146-148.	1.5	3
153	Immature Midbrain Dopaminergic Neurons Derived from Floor-Plate Method Improve Cell Transplantation Therapy Efficacy for Parkinson's Disease. Stem Cells Translational Medicine, 2017, 6, 1803-1814.	3.3	26
154	Intermediate C9orf72 alleles in neurological disorders: does size really matter?. Journal of Medical Genetics, 2017, 54, 591-597.	3.2	52
155	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of Aging, 2017, 49, 217.e1-217.e4.	3.1	7
156	Superoxide drives progression of Parkin/PINK1-dependent mitophagy following translocation of Parkin to mitochondria. Cell Death and Disease, 2017, 8, e3097-e3097.	6.3	90
157	Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310065.	1.9	27
158	MiRNA-128 regulates the proliferation and neurogenesis of neural precursors by targeting PCM1 in the developing cortex. ELife, 2016, 5, .	6.0	67
159	Flow Cytometry-Based Assessment of Mitophagy Using MitoTracker. Frontiers in Cellular Neuroscience, 2016, 10, 76.	3.7	80
160	Neurodegeneration: Etiologies and New Therapies 2016. BioMed Research International, 2016, 2016, 1-1.	1.9	2
161	Transducer-based evaluation of tremor. Movement Disorders, 2016, 31, 1327-1336.	3.9	64
162	PARK16 is associated with PD in the Malaysian population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 839-847.	1.7	11

#	Article	IF	Citations
163	Resveratrol alleviates MPTPâ€induced motor impairments and pathological changes by autophagic degradation of Î±â€synuclein via SIRT1â€deacetylated LC3. Molecular Nutrition and Food Research, 2016, 60, 2161-2175.	3.3	136
164	Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimerâ€™s disease mice. Scientific Reports, 2016, 6, 23964.	3.3	82
165	White matter microstructural characteristics in newly diagnosed Parkinsonâ€™s disease: An unbiased whole-brain study. Scientific Reports, 2016, 6, 35601.	3.3	35
166	Revisiting the link between hypertension and hemifacial spasm. Scientific Reports, 2016, 6, 21082.	3.3	15
167	Vascular tortuosity in relationship with hypertension and posterior fossa volume in hemifacial spasm. BMC Neurology, 2016, 16, 120.	1.8	7
168	Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1148-1152.	1.7	10
169	Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell Stem Cell, 2016, 19, 248-257.	11.1	628
170	Large 3-Mb deletions at 22q11.2 locus in Parkinson's disease and schizophrenia. Movement Disorders, 2016, 31, 1924-1925.	3.9	8
171	Plasma Coenzyme Q10 Levels and Multiple System Atrophy. JAMA Neurology, 2016, 73, 1499.	9.0	0
172	FUS-linked essential tremor associated with motor dysfunction in Drosophila. Human Genetics, 2016, 135, 1223-1232.	3.8	9
173	Clinicopathological correlation of psychosis and brain vascular changes in Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 20858.	3.3	11
174	Chromosomal deletion at 22q11.2 and Parkinson's disease. Lancet Neurology, The, 2016, 15, 538-540.	10.2	4
175	Essential tremor linked TENM4 mutation found in healthy Chinese individuals. Parkinsonism and Related Disorders, 2016, 31, 139-140.	2.2	28
176	Linking a genomeâ€wide association study signal to a LRRK2 coding variant in Parkinson's disease. Movement Disorders, 2016, 31, 484-487.	3.9	8
177	Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 697-702.	1.9	45
178	Neural substrates of excessive daytime sleepiness in early drug naÃ¯ve Parkinson's disease: A resting state functional MRI study. Parkinsonism and Related Disorders, 2016, 24, 63-68.	2.2	38
179	Genetics of essential tremor. Parkinsonism and Related Disorders, 2016, 22, S176-S178.	2.2	46
180	Deterministic Tractography of the Nigrostriatal-Nigropallidal Pathway in Parkinsonâ€™s Disease. Scientific Reports, 2015, 5, 17283.	3.3	39

#	Article	IF	Citations
181	Lrrk2 R1628P variant is a risk factor for essential tremor. Scientific Reports, 2015, 5, 9029.	3.3	18
182	Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinsonâ€™s Disease. Scientific Reports, 2015, 5, 15492.	3.3	24
183	Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. ENeurologicalSci, 2015, 1, 3-6.	1.3	9
184	Prospective longitudinal study of frailty transitions in a community-dwelling cohort of older adults with cognitive impairment. BMC Geriatrics, 2015, 15, 175.	2.7	38
185	Patterns of linkage disequilibrium at PARK16 may explain variances in genetic association studies. Movement Disorders, 2015, 30, 1335-1342.	3.9	8
186	Nonsynonymous variants in MC1R are rare in Chinese Parkinson disease cases. Annals of Neurology, 2015, 78, 152-153.	5.3	9
187	Association Analysis of COQ2 Variant in Dementia and Essential Tremor. Parkinson's Disease, 2015, 2015, 1-4.	1.1	1
188	Sleep Problems in Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-2.	1.1	3
189	EvaluatingLRRK2Genetic Variants with Unclear Pathogenicity. BioMed Research International, 2015, 2015, 1-6.	1.9	6
190	Familial Parkinsonâ€™s Disease/Parkinsonism. BioMed Research International, 2015, 2015, 1-2.	1.9	6
191	A longitudinal study of non-motor symptom burden in Parkinson's disease after a transition to expert care. Parkinsonism and Related Disorders, 2015, 21, 843-847.	2.2	11
192	CHCHD2 and Parkinson's disease. Lancet Neurology, The, 2015, 14, 681-682.	10.2	29
193	Considerations of Long-term Pain Evaluation Postâ€“Deep Brain Stimulation Surgery. JAMA Neurology, 2015, 72, 1077.	9.0	0
194	microRNAs and Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2015, 888, 85-105.	1.6	84
195	Clinical characteristics of leg restlessness in Parkinson's disease compared with idiopathic Restless Legs Syndrome. Journal of the Neurological Sciences, 2015, 357, 109-114.	0.6	23
196	F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. Human Molecular Genetics, 2015, 24, 6314-6330.	2.9	64
197	Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology, 2015, 85, 1039-1042.	1.1	31
198	Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 2433-2439.	3.6	13

#	Article	IF	Citations
199	No Association of Four Candidate Genetic Variants in MnSOD and SYNIII with Parkinson's Disease in Two Chinese Populations. PLoS ONE, 2014, 9, e88050.	2.5	3
200	Analysis of non-synonymous-coding variants of Parkinson's disease-related pathogenic and susceptibility genes in East Asian populations. Human Molecular Genetics, 2014, 23, 3891-3897.	2.9	28
201	Evidence of Inflammatory System Involvement in Parkinsonâ€™s Disease. BioMed Research International, 2014, 2014, 1-9.	1.9	124
202	Global investigation and meta-analysis of the C9orf72 (G ₄ C ₂) _n repeat in Parkinson disease. Neurology, 2014, 83, 1906-1913.	1.1	56
203	In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Molecular Brain, 2014, 7, 73.	2.6	35
204	Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Human Molecular Genetics, 2014, 23, 3157-3165.	2.9	42
205	Amyloid precursor protein regulates neurogenesis by antagonizing miR-574-5p in the developing cerebral cortex. Nature Communications, 2014, 5, 3330.	12.8	44
206	A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinsonâ€™s disease models. Nature Communications, 2014, 5, 3276.	12.8	175
207	DNAJ mutations are rare in Chinese Parkinson's disease patients and controls. Neurobiology of Aging, 2014, 35, 935.e1-935.e2.	3.1	22
208	Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. Free Radical Biology and Medicine, 2014, 68, 220-233.	2.9	16
209	Transcallosal diffusion tensor abnormalities in predominant gait disorder parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 53-59.	2.2	46
210	Abstract T P147: Vitamin D Deficiency is Associated With Stroke in ethnic Chinese but Not South Asians in a Case-Control Study. Stroke, 2014, 45, .	2.0	0
211	SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. Neurology, 2013, 80, 1618-1619.	1.1	36
212	Utility of next-generation sequencing in ataxias. Nature Reviews Neurology, 2013, 9, 614-615.	10.1	1
213	Plasma Vitamin D Levels are Lower among Ethnic Indians in Matched Pairs of Male Acute Ischaemic Stroke Patients of Indian and Chinese Ethnicity. Proceedings of Singapore Healthcare, 2013, 22, 163-165.	0.6	1
214	Abstract WMP53: Vitamin D Levels Are Lower In Acute Ischemic Stroke Patients Compared To Matched Controls. Stroke, 2013, 44, .	2.0	0
215	Whole-genome and whole-exome sequencing in neurological diseases. Nature Reviews Neurology, 2012, 8, 508-517.	10.1	99
216	LRRK2 variant associated with Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1990-1993.	3.1	26

#	Article	IF	Citations
217	Rare and common LRRK2 exonic variants in Parkinson's disease. Lancet Neurology, The, 2011, 10, 869-870.	10.2	5
218	Genetic marker linking inflammation with sporadic Parkinson's disease. Annals of the Academy of Medicine, Singapore, 2011, 40, 111-2.	0.4	1
219	MultipleLRRK2variants modulate risk of Parkinson disease: a Chinese multicenter study. Human Mutation, 2010, 31, n/a-n/a.	2.5	106
220	Linking LINGO1 to essential tremor. European Journal of Human Genetics, 2010, 18, 739-740.	2.8	13
221	Leucine-Rich Repeat Kinase 2-Linked Parkinsonâ€™s Disease: Clinical and Molecular Findings. Journal of Movement Disorders, 2010, 3, 25-31.	1.3	3
222	LRRK2 G2385R modulates age at onset in Parkinson's disease: A multiâ€center pooled analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 1022-1023.	1.7	35
223	Clinically reported heterozygous mutations in the PINK1 kinase domain exert a gene dosage effect. Human Mutation, 2009, 30, 1551-1557.	2.5	12
224	Non-synonymous GIGYF2 variants in Parkinsonâ€™s disease from two Asian populations. Human Genetics, 2009, 126, 425-430.	3.8	17
225	Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. Neurobiology of Aging, 2009, 30, 501-502.	3.1	14
226	Testâ€“retest repeatability of assessing environmental and lifestyle factors in Parkinson's disease. Movement Disorders, 2008, 23, 1032-1036.	3.9	5
227	Pathogenicity of LRRK2 P755L variant in Parkinson's disease. Movement Disorders, 2008, 23, 734-736.	3.9	12
228	Evidence of increased odds of essential tremor in Parkinson's disease. Movement Disorders, 2008, 23, 993-997.	3.9	81
229	Essential tremor and the common LRRK2 G2385R variant. Parkinsonism and Related Disorders, 2008, 14, 569-571.	2.2	15
230	Treatment outcome correlates with knowledge of disease in hemifacial spasm. Clinical Neurology and Neurosurgery, 2008, 110, 813-817.	1.4	14
231	Bilateral trapezius hypertrophy with dystonia and atrophy. Cmaj, 2007, 176, 1702-1703.	2.0	5
232	Neurovascular compression syndromes and hypertension: clinical relevance. Nature Clinical Practice Neurology, 2007, 3, 416-417.	2.5	5
233	Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenetics and Genomics, 2007, 17, 1001-1005.	1.5	46
234	Isolated facial myorhythmia. Journal of the Neurological Sciences, 2007, 252, 36-38.	0.6	11

#	Article	IF	Citations
235	Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. Journal of the Neurological Sciences, 2007, 252, 113-120.	0.6	40
236	Pathogenic mutations in Parkinson disease. Human Mutation, 2007, 28, 641-653.	2.5	212
237	LRRK2 G2019S founder haplotype in the Chinese population. Movement Disorders, 2007, 22, 105-107.	3.9	10
238	Analysis of LRRK2 Gly2385Arg genetic variant in nonâ€Chinese Asians. Movement Disorders, 2007, 22, 1816-1818.	3.9	33
239	Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Movement Disorders, 2007, 22, 1971-1974.	3.9	20
240	Genetics of restless legs syndrome: evidence for a hereditary disorder. Journal of Neurology, 2007, 254, 68-73.	3.6	0
241	Restless Legs Syndrome and Parkinsonâ€™s Disease: Is there an etiologic link?. Journal of Neurology, 2006, 253, vii33-vii37.	3.6	20
242	Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease. Movement Disorders, 2006, 21, 997-1001.	3.9	55
243	Caseâ€“control study of UCHL1 S18Y variant in Parkinson's disease. Movement Disorders, 2006, 21, 1765-1768.	3.9	26
244	Caseâ€“control study of anxiety symptoms in hemifacial spasm. Movement Disorders, 2006, 21, 2145-2149.	3.9	25
245	LRRK2 G2019S and I2020T mutations are not common in Alzheimer's disease and vascular dementia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 549-550.	1.7	8
246	Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 634-636.	1.7	15
247	Genetic Testing in Parkinson Disease. Archives of Neurology, 2006, 63, 1232.	4.5	67
248	Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Annals of the Academy of Medicine, Singapore, 2006, 35, 840-2.	0.4	18
249	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 1-4.	1.7	23
250	Alpha-synuclein mRNA expression in sporadic Parkinson's disease. Movement Disorders, 2005, 20, 620-623.	3.9	48
251	Effect of MDR1 Haplotype on Risk of Parkinson Disease. Archives of Neurology, 2005, 62, 460.	4.5	66
252	Behind the facial twitch: depressive symptoms in hemifacial spasm. Parkinsonism and Related Disorders, 2005, 11, 241-245.	2.2	46

#	Article	IF	Citations
253	Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clinical Genetics, 2004, 66, 353-357.	2.0	33
254	Restless hand symptoms in carpal tunnel syndrome. International Journal of Clinical Practice, 2004, 58, 1000-1002.	1.7	6
255	An urge to move withL-thyroxine: Clinical, biochemical, and polysomnographic correlation. Movement Disorders, 2004, 19, 1365-1367.	3.9	27
256	Severe bruxism following basal ganglia infarcts: insights into pathophysiology. Journal of the Neurological Sciences, 2004, 217, 229-232.	0.6	29
257	Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). Journal of the Neurological Sciences, 2004, 219, 151-155.	0.6	75
258	Genetic analysis of DJ-1 in a cohort Parkinsonâ€™s disease patients of different ethnicity. Neuroscience Letters, 2004, 367, 109-112.	2.1	24
259	Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neuroscience Letters, 2004, 372, 240-244.	2.1	44
260	Psychogenic tics: diagnostic value of the placebo test. Journal of Child Neurology, 2004, 19, 976-7.	1.4	7
261	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. Movement Disorders, 2003, 18, 593-595.	3.9	27
262	Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population. American Journal of Medical Genetics Part A, 2003, 120B, 58-62.	2.4	28
263	Vascular parkinsonism in moyamoya: Microvascular biopsy and imaging correlates. Annals of Neurology, 2003, 54, 836-840.	5.3	12
264	Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neuroscience Letters, 2003, 336, 70-72.	2.1	61
265	Dopamine agonists and their role in Parkinsonâ€™s disease treatment. Expert Review of Neurotherapeutics, 2003, 3, 805-810.	2.8	5
266	Autosomal Dominant Spinocerebellar Ataxias: An Asian Perspective. Canadian Journal of Neurological Sciences, 2003, 30, 361-367.	0.5	9
267	â€œMyorhythmiaâ€•slow facial tremor from chronic interferon alpha-2a usage. Neurology, 2003, 61, 1302-1303.	1.1	29
268	Restless legs syndrome in an Asian population: A study in Singapore. Movement Disorders, 2001, 16, 577-579.	3.9	238
269	Complex movement disorders following bilateral paramedian thalamic and bilateral cerebellar infarcts. Movement Disorders, 2001, 16, 968-970.	3.9	8
270	Trigeminal neuralgia: should MRI be done routinely?. Australian and New Zealand Journal of Medicine, 1998, 28, 827-829.	0.5	5

#	Article	IF	Citations
271	The borderland between epilepsy and movement disorders. , 0, , 333-351.		0